Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05479006 · ClinicalTrials.gov registry record · NA

Determine the Effect of Targeted High-definition Transcranial Direct Current Stimulation (tDCS) on Reducing Post-stroke Upper Limb Motor Impairments

A NA study of Stroke, sponsored by Carle Foundation Hospital.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05479006: Recruiting NA study of Stroke, sponsored by Carle Foundation Hospital.

NCT05479006 is a NA study of Stroke that is actively recruiting participants, run by Carle Foundation Hospital. The registered enrollment target is 30 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05479006, a NA study of Stroke, is actively recruiting participants, sponsored by Carle Foundation Hospital.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Significant motor impairments occur in 80% of individuals after moderate to severe stroke and impact the body side to the lesioned hemisphere. Typical motor impairments involve loss of dexterity with highly prevalent upper limb flexion synergy. Advances in treating flexion synergy impairments have been hampered by a lack of precision rehabilitation. Previous studies suggest and support the role of cortico-reticulospinal tract (CRST) hyperexcitability in post-stroke flexion synergy. CRST hyperexcitability is often caused by damage to the corticospinal tract (CST). We hypothesize that: 1) inhibiting the contralesional dorsal premotor cortex (cPMd) will directly reduce the CRST hyperexcitability and thus, reduce the expression of the flexion synergy; 2) facilitating the ipsilesional primary motor cortex (iM1) will improve the excitability of the damaged CST, therefore reducing the CRST hyperexcitability and the flexion synergy. we propose to use a novel targeted high-definition tDCS (THD-tDCS) to specifically modulate the targeted cortical regions for testing his hypothesis, via the following aims: Aim 1. Evaluate the effect of cathodal THD-tDCS over the cPMd on reducing the CRST hyperexcitability and the expression of flexion synergy. Aim 2. Evaluate the effect of anodal THD-tDCS over the iM1 on improving the excitability of the CST, and determine whether this, thus, also reduces the CRST hyperexcitability and the flexion synergy. Aim 3. Evaluate the confluence effect of bilateral THD-tDCS, i.e., simultaneous cathodal stimulation over the cPMd and anodal over the iM1.

Primary Outcome

This is a neurophysiological measure that determines the use of the ipsilesional corticospinal tract.

Conditions Studied

Interventions

  • DEVICE Transcranial direct current stimulation (high- definition)

Study Locations (1)

Illinois

  • Carle Foundation Hospital - Urbana

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-09-30
Est. Completion 2026-06-30
Phase NA
Carle Foundation Hospital

3 total trials

What NCT05479006 shows while recruiting

NCT05479006 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Transcranial direct current stimulation (high- definition) is the first listed.

NCT05479006 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT05479006 about?

NCT05479006 is a clinical study titled "Determine the Effect of Targeted High-definition Transcranial Direct Current Stimulation (tDCS) on Reducing Post-stroke Upper Limb Motor Impairments". Significant motor impairments occur in 80% of individuals after moderate to severe stroke and impact the body side to the lesioned hemisphere. Typical motor impairments involve loss of dexterity with highly prevalent upper limb flexion synergy. Advances in treating flexion synergy impairments have b...

What is the current status of trial NCT05479006?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-09-30. Estimated completion is 2026-06-30.

What conditions does trial NCT05479006 study?

This clinical trial studies the following conditions: Stroke.

What interventions are being tested in trial NCT05479006?

The interventions under investigation include: Transcranial direct current stimulation (high- definition) (DEVICE).

Who is sponsoring clinical trial NCT05479006?

This trial is sponsored by Carle Foundation Hospital, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05479006 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05479006's enrollment target sits among peer trials

30 301st of 454 higher than 137 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05479006, the US trial registry maintained by the National Library of Medicine. NCT05479006 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.